The global Beri Beri Treatment market was valued at USD 276.26 million in 2025 and is projected to reach USD 718.85 million by 2035, growing at a CAGR of 12.86% during the forecast period from 2026 to 2035.
The market is witnessing strong growth due to the increasing prevalence of thiamine deficiency disorders, rising awareness regarding nutritional deficiencies, and growing demand for vitamin supplementation therapies. Expanding healthcare access, rising alcohol-related deficiency cases, and increasing government nutrition programs in developing economies are further contributing to market expansion globally.
Market growth is strongly supported by the increasing adoption of thiamine supplements, intravenous thiamine therapy, and oral nutritional medications for the treatment of wet beriberi, dry beriberi, and infantile beriberi. Thiamine supplements continue to dominate the treatment segment owing to their effectiveness, affordability, and widespread availability through hospital pharmacies, retail pharmacies, and home care channels. In addition, advancements in diagnostic technologies and growing awareness regarding vitamin B1 deficiency among healthcare professionals are improving early diagnosis and treatment outcomes. Rising demand for preventive healthcare and fortified nutritional products is also accelerating market penetration across emerging economies.
Recent regulatory support and healthcare initiatives are strengthening the future outlook of the market. In 2025, increasing regulatory focus on nutritional deficiency management and public health nutrition programs encouraged pharmaceutical and nutraceutical companies to expand thiamine supplement production and distribution networks globally. The U.S. Food and Drug Administration continues to support the availability and quality regulation of vitamin B1 therapies and nutritional supplements, improving market access and product safety standards. In addition, healthcare organizations and government agencies are increasing investments in food fortification programs and maternal-child nutrition initiatives to reduce vitamin deficiency-related disorders worldwide.
The future outlook for the Beri Beri Treatment market remains positive, supported by increasing awareness regarding micronutrient deficiencies, expanding adoption of preventive nutrition strategies, and growing investments in personalized nutritional healthcare. Integration of digital health platforms, AI-assisted nutritional assessment tools, and remote patient monitoring systems is expected to improve treatment adherence and early deficiency detection. Furthermore, ongoing research involving advanced vitamin formulations, fortified food technologies, and targeted nutritional therapies is likely to create significant growth opportunities for pharmaceutical and nutraceutical companies over the coming years.
Beri Beri Treatment Market Scope
| Metrics | Details |
| Market CAGR | 7% |
| Segments Covered | By Type, By Drug Type, By End-User, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
Beri Beri Treatment Market Dynamics
The factors influencing the global beri beri treatment market are the increasing research and development and the growing prevalence of thiamine deficiency.
The increasing research and development is expected to drive the market growth in the forecast period
Edema, breathlessness, muscle weakness, and beriberi, a sheep-like gait pattern, are all symptoms of thiamine deficiency. Thiamine is a water-soluble vitamin that cannot be stored in significant quantities. Surgery, fasting, strenuous activity, fever, sepsis, pregnancy, breastfeeding, adolescent growth, and anorexia increase thiamine requirements. Acute or fulminant beriberi can result from an increased requirement for thiamine or a decrease in thiamine consumption after a gastrectomy, with aging patients being more susceptible. Beriberi can develop many years after gastrectomy and go unnoticed by doctors, resulting in treatment delays. It's critical to recognize and treat beriberi as soon as possible, as well as a rule out other possible diagnoses. Beriberi is a nutritional complication of gastric surgery that has life-threatening clinical implications. Because thiamine is absorbed in the duodenum and proximal jejunum, patients with a total gastrectomy, Billroth II gastrectomy, or Roux-en-Y diversion are at an increased risk. Beriberi has also been reported after laparoscopic sleeve gastrectomy, gastroplasty, and laparoscopic adjustable gastric banding. After upper gastrointestinal surgery, patients frequently have subclinical thiamine deficiency. Thiamine deficiency causes glucose metabolism problems, reduced oxygen delivery by red blood cells, cardiac dysfunction, axonopathy, neurotransmission failure, and neuron death. Moreover, for men and women, the Recommended Dietary Intake (RDI) of oral thiamine is 1.2 mg and 1.1 mg, respectively, and the daily Estimated Average Requirement (EAR) is 1.0 mg and 0.9 mg. Sensorimotor peripheral neuropathy, Wernicke encephalopathy, Korsakoff psychosis (dry beriberi), cardiac failure, edema, and arrhythmia are symptoms of thiamine deficiency (wet beriberi).
The side effects associated with beriberi treatment are expected to hamper the market growth
The side effects associated with thiamine are severe allergic reaction to heat (anaphylaxis), discoloration of the skin, sweating \srestlessness, hives with rapid skin swelling and itching, inflammation of the lungs (pulmonary edema), weakness, nausea throat constriction.
There are no known serious interactions between thiamine and other medications. The following are examples of thiamine interactions moderate azithromycin \sclarithromycin, erythromycin lactobionate, erythromycin stearate, erythromycin base erythromycin ethylsuccinate, and roxithromycin. At least 69 different drugs have mild interactions with thiamine. Hence, the side effects and interactions associated with thiamine are expected to hamper market growth.
COVID-19 Impact Analysis
Thiamine as adjunctive therapy may improve survival in COVID-19 patients who are critically ill. Additionally, it was linked to a reduced risk of thrombosis. Systemic thiamine administration may be considered part of COVID-19 management during ICU admission. The role of thiamine in COVID-19 patients is still unknown; however, it has been studied extensively in critically ill patients. Moskowitz et al. found that thiamine was linked to significantly lower lactate levels, serum creatinine, and a possible reduction in 30-day mortality in a randomized controlled trial. In addition, thiamine administration within 24 hours was linked to improved lactic acid clearance and lower 28-day mortality in critically ill patients with septic shock. Hence, the increasing demand for thiamine during covid-19 is expected to positively impact the market.
Beri Beri Treatment Market Segment Analysis
Wet Beriberi segment is expected to dominate the market growth
Thiamine deficiency with cardiovascular involvement is referred to as wet beriberi. There are three stages to the chronic form of wet beriberi. Peripheral vasodilation occurs in the first stage, resulting in a high cardiac output state. This causes salt and water retention in the kidneys, mediated by the renin-angiotensin-aldosterone system. The kidneys detect a relative volume loss as the vasodilation progresses and respond by conserving salt. Fluid is absorbed into the circulatory system as a result of salt retention. Edema of the dependent extremities occurs as a result of fluid overload.
Acute fulminant cardiovascular beriberi, also known as Shoshin beriberi, is a faster form of wet beriberi. The heart is the most commonly injured organ, and rapid deterioration results from the heart muscle's inability to meet the body's demands due to its injury. Edema may not be present in this case. Instead, cyanosis of the hands and feet, tachycardia, dilated neck veins, restlessness, and anxiety are experienced. Because systemic vasoconstriction is restored before the heart muscle recovers, thiamine treatment causes low-output cardiac failure. Vitamin B1 therapy can help with the diagnosis and treatment of wet beriberi. It is widely accepted that patients suspected of having thiamine deficiency should receive therapeutic thiamine administration.
Beri Beri Treatment Market Geographical Analysis
North America region is expected to hold the largest market share in the global beri beri treatment market
Due to high healthcare costs and high-quality medical facilities, the vast majority of the population is covered by insurance. The presence of key players in the market is expected to drive market growth. For instance, the company Fresenius Kabi USA’s thiamine hydrochloride injection, USP, is effective for treating berberi.
Beri Beri Treatment Market Competitive Landscape
The global beri beri treatment market is moderately competitive. Some of the key players in the market are Fresenius Kabi USA, LLC, GlaxoSmithKline plc, Parex Pharmaceuticals Pvt. Ltd., Solgar, EZ Melts, Bulk Supplements, DSM, AdvaCare Pharma.
Fresenius Kabi USA
Overview: Fresenius Kabi is a global healthcare company specializing in infusion, transfusion, and clinical nutrition medicines and technologies. The company has headquarters in Illinois, United States, founded in 1912.
Product Portfolio: Thiamine hydrochloride injection, USP is a sterile solution of thiaminehydrocholride in water for injection for intramuscular (IM) or slow intravenous (IV) administration. It is effective for the treatment of berberi.
